Avantor (AVTR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Avantor, Inc. reported revenue of $1.69 billion for the quarter ended December 2024, a decrease of 2.1$0.27, up from $0.25 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of$1.71 billion, resulting in a surprise of -1.45%, while the EPS exceeded expectations by 8% [1] Revenue Performance - Bioscience Production revenue was $560.80 million, slightly below the estimated$563.83 million [4] - Laboratory Solutions revenue reached $1.13 billion, compared to the average estimate of$1.16 billion [4] Operating Income - Adjusted Operating Income for Laboratory Solutions was $147.40 million, close to the estimate of$147.52 million [4] - Adjusted Operating Income for Corporate was -$17.20 million, worse than the estimated -$16.03 million [4] - Adjusted Operating Income for Bioscience Production was $149.20 million, exceeding the average estimate of$139.91 million [4] Stock Performance - Avantor's shares have returned -1.9% over the past month, contrasting with the Zacks S&P 500 composite's +1.9% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market [3]